The Predictive Value of Baseline HBs Ag Level and Early Response for HBs Ag Loss in Patients with HBe Ag-positive Chronic Hepatitis B during Pegylated Interferon Alpha-2a Treatment

Objective To explore the predictive value of baseline HBs Ag level and early response for HBs Ag loss in patients with HBe Ag-positive chronic hepatitis B during pegylated interferon alpha-2a treatment. Methods A total of 121 patients with HBe Ag-positive chronic hepatitis B who achieved HBs Ag loss were enrolled; all patients were treated with PEG-IFNα-2a 180 μg/week. Serum HBV DNA and serological indicators （HBs Ag, anti-HBs, HBe Ag, and anti-HBe） were determined before and every 3 months during treatment. Results The median treatment time for HBs Ag loss was 84 weeks （7-273 weeks）, and 74.38% （90 cases） of the patients needed extended treatment （〉 48 weeks）. The correlation between baseline HBs Ag levels and the treatment time of HBs Ag loss was significant （B = 14.465, t = 2.342, P = 0.021）. Baseline HBs Ag levels together with the decline range of HBs Ag at 24 weeks significantly correlated with the treatment time of HBs Ag loss （B = 29.862, t = 4.890, P = 0.000 and B = 27.993, t = 27.993, P = 0.005）. Conclusion Baseline HBs Ag levels and extended therapy are critical steps toward HBs Ag loss. Baseline HBs Ag levels together with early response determined the treatment time of HBs Ag loss in patients with HBe Ag-positive chronic hepatitis B during pegylated interferon alpha-2a treatment.

Combination Therapy with Pegylated Interferon alpha-2b and Adefovir Dipivoxil in HBeAg-positive Chronic Hepatitis B versus Interferon Alone: A Prospective, Randomized Study

Currently available monotherapies of oral nucleoside/nucleotide analogs or interferon are unable to achieve a sustained and effective response in most of patients with chronic hepatitis B（CHB）. The objective of the present study was to compare the efficacy and safety of pegylated interferon（Peg-IFN） alpha-2b plus adefovir dipivoxil combination therapy versus Peg-IFN alpha-2b alone. Sixty-one HBeAg-positive chronic hepatitis B patients were randomized to receive Peg-IFN alpha-2b alone（1.5 μg/kg once weekly） or Peg-IFN alpha-2b plus adefovir（10 mg daily） for up to 52 weeks. Efficacy and safety analyses were performed on all participants who received at least one dose of study medication. The rate of HBeAg seroconversion and undetectable HBV-DNA were evaluated after 52 weeks of therapy. At the end of treatment, 11 of 30（36.7%） patients receiving combination therapy achieved HBeAg seroconversion versus 8 of 31（25.8%） in the monotherapy group（P=0.36）. In contrast, the percentage of patients with undetectable serum HBV DNA was significantly higher in the combination group than in the monotherapy group（76.7% vs. 29.0%, P〈0.001）. Thyroid dysfunction was more frequent in the combination group than in the monotherapy group（P〈0.05）. In HBeAg-positive CHB, combination of Peg-IFN alpha-2b and adefovir for 52 weeks resulted, at the end of treatment, in a higher virological response but without significant impact on the rate of HBeAg seroconversion and possibly an adverse effect on thyroid function.

重组人干扰素α-2b乳膏治疗带状疱疹和生殖器疱疹

[目的 ]通过干扰素α - 2b乳膏治疗带状疱疹和生殖器疱疹 ,评价该药的临床疗效与安全性。[方法 ]采用随机双盲、平行对照试验。试验组和对照组各 4 0例 ,皮疹处外涂干扰素α - 2b乳膏或安慰剂 ,4次 /d。 [结果 ]生殖器疱疹试验组痊愈率 6 5 % ,有效率 85 % ;对照组痊愈率 2 5 % ,有效率5 0 %。带状疱疹试验组痊愈率 6 0 % ,有效率 85 % ;对照组痊愈率 1 5 % ,有效率 4 5 %。两种疾病的试验组疗效均明显优于对照组 ,统计学分析具有显著性差异 (P <0 .0 5 )。未见不良反应。 [结论 ]重组人干扰素α - 2b乳膏治疗生殖器疱疹和带状疱疹安全。

维A酸乳膏联合重组人干扰素α-2b凝胶治疗扁平疣疗效的影响

目的分析扁平疣采用维A酸乳膏联合重组人干扰素α-2b凝胶治疗的临床疗效。方法选取该院2018年7月—2019年7月收治的84例扁平疣患者为研究对象,按照随机数字表法分为两组,对照组仅采用维A酸乳膏治疗,观察组在对照组基础上联合重组人干扰素α-2b凝胶治疗,对比两组临床疗效、治疗前后T淋巴细胞亚群指标变化情况以及不良反应发生情况。结果观察组治疗总有效率为95.23%,高于对照组的71.43%(χ^2=8.571,P<0.05);观察组治疗后CD4^+、CD8^+、CD4^+/CD8^+分别为(44.28±2.28)%、(30.02±1.98)%、(1.52±0.38),均高于对照组(t=12.148、13.259、10.256,P<0.05);对照组不良反应发生率为21.43%(9/42),观察组为23.81%(10/42),对比差异无统计学意义(χ^2=0.068,P>0.05)。结论扁平疣采用维A酸乳膏联合重组人干扰素α-2b凝胶治疗的临床疗效显著,且安全性高。

5%咪喹莫特乳膏治疗传染性软疣的疗效观察

目的：观察5%咪喹莫特软膏治疗传染性软疣的临床疗效及安全性。方法选取2014年5～10月门诊确诊的传染性软疣患者90例，随机分为治疗组和对照组各45例。治疗组予5%咪喹莫特软膏治疗，对照组予重组人干扰素α-2b乳膏治疗并加用他扎罗汀凝胶。2组治疗期间均每周复诊1次，连续观察4周，疗程结束时判定疗效。结果治疗组第1、2、3、4周有效率均优于对照组，差异有统计学意义（ P＜0.05）。结论5%咪喹莫特乳膏治疗传染性软疣，疗效确切，不良反应小，安全性高，值得临床推广应用。

Study of recombinant human IFN-α-2b bacilli Calmette–Guerin activated killer cells and against bladder cancer cell in vitro

Presently,one of the most potent immunothera-pies is the application of bacillus Calmette Guerin(BCG)to prevent recurrences of the superficial bladder cancer.Despite its successful use,nonresponders and certain side effects remain a major obstacle.Therefore,current studies aim at developing recombinant BCG(rBCG)strains secreting Th1-like cytokines to improve the effectiveness of the therapy.In this study,a new type of rBCG strain constructed by Tianjin institute of Urology was tested for its immunostimulatory capacity in vitro.Peripheral blood monocytes(PBMC)were stimulated by recombinant BCG and transformed into bacilli Calmette–Guerin activated killer(BAK)cells,and the effect of anticancer BAK cells was studied.Recombinant IFN-a-2b-BCG,wild-type BCG(wBCG),wild-type BCG and IFN-a-2b were coincubated with PBMCs respectively in vitro,and the proliferation of PBMC was detected with MTT in different time.BAK cells have the ability to kill bladder tumor cells,and the antitumor activity of effecter cells was determined by LDH release assay.The result of MTT showed that the proli-feration of PBMC in the recombinant BCG group was more powerful than in the other two groups(P<0.05).The result of LDH release assay showed that the antitumor activity of BAK cells stimulated by Recombinant BCG was the highest in all groups.We conclude that the recombinant BCG can activate more PBMCs to anti-bladder cancer in vitro than wild-type BCG does.